Search Results 71-80 of 15066 for Tamoxifen
The purpose of this study is to compare the effectiveness of fulvestrant to anastrozole or tamoxifen in treating invasive lobular breast cancer, by measuring ...
CHICAGO — Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by ...
Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the ...
Taking the hormone therapy medicine tamoxifen for breast cancer can increase the risk of developing endometrial cancer. If you're taking tamoxifen, talk about ...
Pogorelova MO, Buzzard JA, Fischer KM, Salonen BR, Klassen CL. Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at ...
Tamoxifen was one of the first breakthroughs in hormone-targeted therapy. Two decades later, trastuzumab transformed outcomes for HER2-positive breast ...
Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to ...
... (tamoxifen if pre-menopausal; aromatase inhibitor if post-menopausal). NOTE: exception: patients that fail (defined as the development of metastatic disease ...
... tamoxifen; Developing a new drug to replace tamoxifen for people with low CYP2D6 enzyme activity; Developing a new drug for women with resistance to aromatase ...
Treatment adherence and its impact on disease-free survival in the Breast International Group I-98 trial of tamoxifen and letrozole, alone and in sequence.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.